Brexit | The RSA Group

Providing leadership for the life sciences industry

Our Services
Our Teams
Why we are Different
Talent Matters
News & Views
Candidates
Contact Us

Recent posts

Attracting the Best Life Sciences Talent After Brexit
November 18, 2019
IQ might get you hired but EQ will get you promoted
November 7, 2019
Who can put a price on cell and gene therapy?
October 17, 2019
Unleashing The Power of Interims
October 11, 2019
RSA Talent Talks debut Podcast
October 2, 2019

Follow us

The RSA Blog
The RSA Group on LinkedIn
The RSA Group on Twitter
The RSA Group on YouTube

Popular tags

Better Hiring Big Data Big Pharma Biotech Boards Brexit cell therapy CEO Choice Consultant Consumer Health CRO CSO Deloitte's Digital Healthcare Diversity Due Diligence Executive Search Freelancer gene therapy Global market Healthcare HTA Immuno-oncology insights Interims IP JP Morgan Leadership Life Sciences M&A Maximise Success medtech Med Tech Partner Pharma Preclinical Proof of Candidate R&D Regulatory science leadership SMEs Strategic Thinking Supply Chain Talent Talent Equity Thought Leadership TOPRA UK Biotech Valuation

View Archives »

Spotlight On

Read the report Catch up on RSA's blog: Talent Matters

The latest RSA News

RSA Announces Debut Podcast | RSA Talent Talks Cell & Gene Therapy
RSA Viewpoint | 2019 Outlook
Phil Tomlinson and Prad Mistry join The RSA Group’s Interims Service as Business Development Directors
RSA Viewpoint | Why we should stop talking about Diversity & Inclusion Initiatives
Sam Faulkner joins The RSA Group as Consultant

The RSA Blog
The RSA Group on LinkedIn
The RSA Group on Twitter
The RSA Group on YouTube

RSA Consulting Limited
Registered office: 4 Devonshire Street, London W1W 5DT
Registered in England: company registration number 1803896

Website: Terms of use | Privacy policy | Cookie policy

Design by jcreative.co.uk

This website uses cookies to improve your experience. Accept Read More

Privacy & Cookies Policy

Necessary Always Enabled